Toripalimab
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-TORIPALIMAB |
|---|---|
| Type | Drug |
| Aliases | JS001LoqtorziTuoyitoripalimab-tpziТорипалімаб |
| Status | reviewed 2026-07-11 | pending_clinical_signoff |
| Diseases | DIS-NPC |
| Sources | SRC-JUPITER-02-MAI-2021 |
Drug Facts
| Class | Anti-PD-1 humanized IgG4 monoclonal antibody (immune checkpoint inhibitor) |
|---|---|
| Mechanism | Humanized IgG4 monoclonal antibody binding the programmed cell death protein 1 (PD-1) receptor on activated T cells, blocking PD-1/PD-L1 and PD-1/PD-L2 interactions and restoring cytotoxic T-cell antitumor activity. Same general anti-PD-1 mechanistic class as pembrolizumab (DRUG-PEMBROLIZUMAB) and nivolumab (DRUG-NIVOLUMAB). Studied specifically in EBV-associated nasopharyngeal carcinoma (NPC), a tumor type with a distinctly inflamed, EBV-antigen-driven immune microenvironment. |
| Typical dosing | Per US FDA label (Loqtorzi) and the JUPITER-02 trial protocol: toripalimab 240 mg IV every 3 weeks, combined with gemcitabine + cisplatin (GP) for up to 6 cycles, followed by toripalimab monotherapy (240 mg IV q3w, or 480 mg IV q6w per label) until disease progression, unacceptable toxicity, or up to 2 years total. STUB — dosing drafted from trial-protocol/label recall; pending Clinical Co-Lead confirmation against the primary FDA label text. |
| Ukraine registered | False |
| NSZU reimbursed | False |
Notes
STUB — draft entity pending Clinical Co-Lead sign-off (CHARTER §6.1; currently dev-mode-exempted). Anti-PD-1 backbone of NPC metastatic 1L combination per JUPITER-02 (Mai HQ et al., Nat Med 2021): toripalimab + gemcitabine + cisplatin significantly improved PFS/ORR vs chemo alone in treatment-naive recurrent/metastatic NPC, leading to FDA approval (Loqtorzi) Oct 2023. Reuse this entity rather than duplicate. Distinct from camrelizumab (DRUG-CAMRELIZUMAB), a separate anti-PD-1 antibody studied in CAPTAIN-1st for the same indication — not interchangeable identities despite similar mechanism/regimen role.
Used By
Drug
DRUG-CAMRELIZUMAB- Camrelizumab
Regimens
REG-NPC-GC-TORIPALIMAB- Toripalimab + gemcitabine + cisplatin (JUPITER-02) — 1L recurrent/metastatic nasopharynge...